At week @ , the brodalumab @-mg and @-mg groups had higher rates of ACR @ than the placebo group ( @ % -LSB- P = @ -RSB- and @ % -LSB- P = @ -RSB- , respectively , vs. @ % ) ; they also had higher rates of @ % improvement ( ACR @ ) ( @ % -LSB- P = @ -RSB- and @ % -LSB- P = @ -RSB- vs. @ % ) .